Drugs / PN20
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06880081 | Mar 2025 → Feb 2026 overdue | autoimmune thrombocytopenia | Chongqing Peg-Bio Biopharm Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06521931 | Dec 2023 → Jan 2025 | thrombocytopenia | Chongqing Peg-Bio Biopharm Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06523088 | Jun 2022 → Jan 2023 | autoimmune thrombocytopenic purpura | Chongqing Peg-Bio Biopharm Co., Ltd. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07446491 | Jun 2025 → May 2026 overdue | thrombocytopenia | Chongqing Peg-Bio Biopharm Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PN20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06880081 ↗ |
| Action | Activate | “thrombopoietin receptor agonist” NCT06523088 ↗ |
| Modality | Peptide | “Polyethylene Glycolated Thrombopoietin Peptide” NCT07446491 ↗ |
| Route | Subcutaneous | “subcutaneous injections” NCT06521931 ↗ |